Neurofibrosarcoma Trials in Disease

Study of Long-term Safety of Tazemetostat in Patients Who Previously Participated in Tazemetostat Clinical Trials

This trial is designed to monitor the long-term safety of tazemetostat in patients who have already been treated with this medication in previous clinical studies and have experienced clinical benefit. The study will track how well patients tolerate the medication over an extended period and monitor for any side effects that may develop during continued treatment.

Inclusion criteria: To participate in this trial, you must currently be receiving tazemetostat treatment and benefiting from it. The medication may be taken alone or in combination with other approved or experimental treatments. You must have a life expectancy of more than 3 months and demonstrate adequate blood cell counts, bone marrow function, blood clotting factors, kidney function, and liver function. Women who can become pregnant must have a negative pregnancy test at the start of the study and agree to use highly effective birth control methods plus a barrier method during treatment and for 6 months afterward. Men must either have had a vasectomy and remain abstinent or use effective contraception, including condoms, throughout the study and for 3 months after stopping treatment.

Exclusion criteria: You cannot participate if you are not currently receiving tazemetostat in a previous clinical study, or if you experienced severe side effects during previous treatment with this medication. Patients who cannot comply with long-term safety monitoring requirements, who have developed medical conditions that make continued treatment unsafe, or who have withdrawn consent from their previous tazemetostat study are not eligible. Additionally, you cannot participate if you have missed scheduled doses, failed to follow study procedures in your previous trial, developed progressive disease while on tazemetostat, are participating in other clinical trials simultaneously, have developed contraindications to tazemetostat treatment, or cannot attend long-term follow-up visits as required.

Focus of the trial: The main goal of this study is to evaluate the long-term safety of tazemetostat when used continuously by patients who have shown benefit from the treatment in previous trials. Researchers will carefully monitor participants for any side effects and track various health measures including blood cell counts, kidney function, and liver function. The study will also monitor how long patients survive while receiving the treatment. Treatment will continue according to each patient's previous treatment plan, and participation will last as long as the patient continues to show clinical benefit. The study is planned to continue until September 2025.

Investigational drug: Tazemetostat is an oral medication given as a film-coated tablet. It belongs to a class of drugs called EZH2 inhibitors, which work by blocking the EZH2 protein that plays a crucial role in controlling gene expression and cancer cell growth. This medication targets specific enzymes in cancer cells to help control the growth of certain types of tumors. Tazemetostat represents an innovative approach in targeted cancer therapy and is primarily used in the treatment of certain types of lymphomas and solid tumors, showing particular effectiveness in patients with specific genetic mutations.